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ABSTRACT
   Cancer is fundamentally a genetic and epigenetic disease that requires the accumulation of genomic alterations 
that inactivate tumor suppressors and activate proto-oncogenes.  Two contradicting epigenetic events coexist in 
cancer: global hypomethylation, which is mainly observed in repetitive sequences within the genome, and regional 
hypermethylation, which is frequently associated with CpG islands within gene promoters.  Hypermethylation alters 
the activity in a number of important signaling pathways by silencing expression of genes encoding Wnt antagonists, 
negative Ras effectors, and p53 targets.  The list of genes aberrantly methylated in cancer is growing, and methylation 
of a p53 target micoRNA gene has been recently demonstrated.  Global hypomethylation is strongly implicated in 
chromosomal instability and malignant potential of tumors.  Sites of aberrant DNA methylation could be promising 
markers and targets for risk assessment, early detection and treatment of cancer.
(Accepted October 26, 2010)
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